Delivery Order SPE2DB24D2216-SPE2DB25FGPQH
- Not listed
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (quantity 28) under a firm fixed-price contract. The order, valued at $7,575.75, was competitively awarded without a set-aside designation and is scheduled for completion by August 8, 2025. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count packaging) under a firm fixed price contract type. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) under a firm fixed price contract. This non-competitive set-aside delivery order is scheduled for completion by September 2, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services through AmerisourceBergen's extensive federal...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count package), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed from the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,116.87 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on August 18, 2025. The contract is structured as a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $8,116.87 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) under a firm fixed-price contract. This delivery order, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The contract utilizes a delivery order mechanism,...
- The Defense Logistics Agency awarded a delivery order valued at $37,878.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPQHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count) with an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order executed on August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order operates under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp's federal contract portfolio demonstrates extensive capability in fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, from specialty medications to brand-name and generic drugs, positioning the company as a primary vendor for the DLA's pharmaceutical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/21/25 |